The CASP9 Knockout HT29 Polyclonal Cells consist of a heterogeneous population of HT-29 colorectal adenocarcinoma cells with CRISPR/Cas9-mediated disruption of the CASP9 gene. This polyclonal knockout pool provides a robust loss-of-function model for studying the intrinsic apoptotic pathway without the constraints of clonal selection. The product is designed for investigations into apoptosis signaling, drug response, and tumor biology in a disease-relevant colon cancer background.
HT-29 is a widely used human colon adenocarcinoma cell line derived from a primary tumor. It exhibits epithelial morphology and carries mutations in key cancer-related genes such as APC, TP53, and KRAS, making it a pertinent model for colorectal cancer research. The HT-29 background offers a physiologically relevant context for assessing the impact of CASP9 deletion on apoptotic signaling and tumor cell survival.
CASP9 encodes the initiator caspase of the intrinsic apoptosis cascade. Upon mitochondrial cytochrome c release, it forms the apoptosome complex with APAF1, leading to its activation. Active CASP9 then proteolytically processes executioner caspases-3 and -7, which degrade downstream substrates including PARP1 and DFFA/ICAD. Upstream, CASP9 is regulated by BAX/BAK-mediated mitochondrial permeabilization and p53-dependent transcription. The anti-apoptotic protein XIAP directly inhibits CASP9, while Bcl-2 family members control cytochrome c release. Thus, CASP9 knockout uncouples mitochondrial outer membrane permeabilization from executioner caspase activation.
In HT-29 colon cancer cells, CASP9 disruption models the apoptotic resistance commonly observed in colorectal tumors. This polyclonal knockout population allows researchers to examine how loss of the intrinsic apoptotic gateway affects cellular responses to chemotherapeutic agents that induce mitochondrial stress. Because HT-29 cells are extensively characterized in the literature, the model supports elucidation of compensatory survival mechanisms and identification of alternative cell death pathways that may be therapeutically targeted.
Research applications include western blot profiling of caspase-9, -3, and -7 cleavage; caspase activity assays using fluorogenic or luminescent substrates; flow cytometric quantification of apoptosis via annexin V/propidium iodide staining; cytochrome c release measurements from fractionated mitochondria; and cell viability assessments such as MTT assays. Comparative experiments with the parental HT-29 parental line allow direct linkage of phenotypic alterations to CASP9 loss. For further information or tailored experimental support, contact Ascent Research.
